Medpace Hldgs: Q2 Earnings Insights
Shares of Medpace Hldgs (NASDAQ:MEDP) moved higher by 15.7% in after-market trading after the company reported Q2 results.
Quarterly Results
Earnings per share decreased 20.99% over the past year to $0.64, which beat the estimate of $0.40.
Revenue of $204,995,000 decreased by 4.25% year over year, which beat the estimate of $174,970,000.
Guidance
The upcoming fiscal year's EPS expected to be between $3.62 and $3.83.
The upcoming fiscal year's revenue expected to be between $880,000,000 and $920,000,000.
Price Action
Company's 52-week high was at $114.12
52-week low: $58.72
Price action over last quarter: Up 33.19%
Company Description
Medpace Holdings Inc is a clinical contract research organization. It is engaged in scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries. It operates in North America, Europe, Africa, Middle East, Asia-Pacific and Latin America.
See more from Benzinga
© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
